Company: CYTK
Filing Date: 2025-03-31
Form Type: PRE 14A
Source: 0001140361-25-011212
Chunk: 59

Company: CYTOKINETICS INC
Filing Date: 2025-03-31
Form: PRE 14A
Chunk 59
---
 executive compensation levels relative to the market. Companies are evaluated and adjusted as appropriate for inclusion in these analyses based on business characteristics similar to ours. Potential companies are selected based on criteria that include business model, stage of development, market capitalization, years since its initial public offering, employee headcount, research and development expenditures, cash reserves and revenue.

| Cytokinetics, Inc.|2025 Proxy Statement |     | 41 |

TABLE OF CONTENTS Executive Compensation

When the 2023 peer group was established in November 2022, the Company’s market capitalization was approximately $3 billion and headcount was less than 400 employees. Accordingly, in January 2024, the Compensation Committee, in consultation with its independent consultation consultant, made meaningful changes to the peer group selection criteria and resulting peer companies to account for the advancement of the Company’s clinical assets, significant growth in the Company’s market capitalization relative to the prior year, and meaningful year-over-year increase in headcount. The Compensation Committee approved the following Peer Companies for use in making compensation decisions in 2024:

| • |     | ACADIA Pharmaceuticals Inc.     |     | • |     | INSMED Inc.                     |
| • |     | Amicus Therapuetics, Inc.       |     | • |     | Ionis Pharmaceuticals, Inc.     |
| • |     | Apellis Pharmaceuticals, Inc.   |     | • |     | Karuna Therapeutics, Inc.       |
| • |     | Arrowhead Pharmaceuticals, Inc. |     | • |     | Legend Biotech Corp             |
| • |     | Ascendis Pharma A/S             |     | • |     | Madrigal Pharmaceuticals, Inc.  |
| • |     | Blueprint Medicines Corporation |     | • |     | Mirati Therapeutics, Inc.       |
| • |     | BridgeBio Pharma, Inc           |     | • |     | Neurocrine Biosciences, Inc.    |
| • |     | Denali Therapeutics Inc.        |     | • |     | Sarepta Therapeutics, Inc.      |
| • |     | Halozyme Therapeutics, Inc.     |     | • |     | Ultragenyx Pharmaceuticals Inc. |
| • |     | Immunovant, Inc.                |     | • |     | Vaxcyte, Inc.                   |
| • |     | Intra-Cellular Therapies, Inc.